andecaliximab + S-1 + cisplatin

A combination therapy of **andecaliximab**, **S-1**, and **cisplatin** is under investigation, particularly as a first-line treatment for patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. - **Andecaliximab** is a monoclonal antibody that selectively inhibits **matrix metalloproteinase 9 (MMP9)**, an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis. By binding and neutralizing MMP9, andecaliximab may disrupt tumor progression and enhance the cytotoxic effects of chemotherapy[4][5]. - **S-1** is an oral fluoropyrimidine prodrug composed of tegafur (a prodrug of 5-fluorouracil), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (which reduces gastrointestinal toxicity), acting as an antimetabolite that inhibits DNA synthesis in rapidly dividing cancer cells. - **Cisplatin** is a platinum-based chemotherapeutic that forms DNA crosslinks, disrupting DNA synthesis and leading to apoptosis in cancer cells. Together, these agents theoretically provide synergistic effects through complementary mechanisms: inhibition of tumor microenvironment remodeling (andecaliximab), direct tumor cytotoxicity (S-1, cisplatin), and prevention of metastasis. In phase Ib clinical studies, this combination has shown tolerability and is being further explored for efficacy in gastric and GEJ cancers[4].

Other names

ADX + S-1 + cisplatin